Discover undervalued stocks with Eulerpool.

Subscribe for $2

ANI Pharmaceuticals Stock ANIP

Price

0
Today +/-
-0
Today %
-0 %

ANI Pharmaceuticals stock price

Loading chart...
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the ANI Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the ANI Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the ANI Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze ANI Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

ANI Pharmaceuticals Stock Price History

DateANI Pharmaceuticals Price
10/1/20250 undefined
10/1/202590.19 undefined
9/29/202591.60 undefined
9/28/202591.93 undefined
9/25/202593.05 undefined
9/24/202593.37 undefined
9/24/202595.00 undefined
9/23/202595.38 undefined
9/22/202595.94 undefined
9/19/202596.79 undefined
9/18/202597.49 undefined
9/17/202595.37 undefined
9/16/202597.56 undefined
9/15/202598.82 undefined
9/12/202598.20 undefined
9/11/202598.43 undefined
9/10/202597.47 undefined
9/9/202597.17 undefined
9/8/202595.21 undefined
9/5/202595.36 undefined
9/4/202595.88 undefined
9/3/202594.90 undefined
9/2/202593.63 undefined

ANI Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into ANI Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by ANI Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects ANI Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of ANI Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into ANI Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing ANI Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on ANI Pharmaceuticals’s growth potential.

ANI Pharmaceuticals Revenue, EBIT and net profit per share

DateANI Pharmaceuticals RevenueANI Pharmaceuticals EBITANI Pharmaceuticals Net Income
2030e1.13 B undefined0 undefined224.3 M undefined
2029e1.07 B undefined166.06 M undefined200.83 M undefined
2028e1.02 B undefined137.9 M undefined187.27 M undefined
2027e1.03 B undefined286.92 M undefined180.2 M undefined
2026e937.14 M undefined253.33 M undefined156.35 M undefined
2025e856.21 M undefined224.35 M undefined142.81 M undefined
2024614.38 M undefined2.84 M undefined-20.15 M undefined
2023486.82 M undefined48.1 M undefined15.48 M undefined
2022316.4 M undefined-29.5 M undefined-49.5 M undefined
2021216.1 M undefined-27.9 M undefined-42.8 M undefined
2020208.5 M undefined-4.3 M undefined-22.5 M undefined
2019206.5 M undefined23.2 M undefined6 M undefined
2018201.6 M undefined35.4 M undefined15.3 M undefined
2017176.8 M undefined29.2 M undefined-1.1 M undefined
2016128.6 M undefined26.8 M undefined3.9 M undefined
201576.3 M undefined32.7 M undefined15.3 M undefined
201456 M undefined20 M undefined28.6 M undefined
201330.1 M undefined900,000 undefined-4.7 M undefined
201220.4 M undefined0 undefined-8.4 M undefined
2011400,000 undefined-50.9 M undefined-51.6 M undefined
20102.5 M undefined-43.6 M undefined-46.2 M undefined
20091.3 M undefined-38.4 M undefined-47.5 M undefined
20083.8 M undefined-18 M undefined-17.4 M undefined
2007500,000 undefined-8.7 M undefined-7.6 M undefined
200614.4 M undefined2.4 M undefined2.8 M undefined
2005300,000 undefined-10.1 M undefined-9.7 M undefined

ANI Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M)
NET INCOME (M)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
1998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025e2026e2027e2028e2029e2030e
000000000.01000000.020.030.060.080.130.180.20.210.210.220.320.490.610.860.941.031.021.071.13
----100.00-------66.67100.00--50.0086.6735.7168.4237.5014.202.490.973.8546.3053.8026.3439.419.469.61-0.294.395.80
---36,400.0018,200.00---71.43-100.00100.00100.00-55.0066.6778.5782.8961.7255.1163.6869.4258.1753.2456.0162.7659.2842.5238.8535.4435.5534.0532.18
000000001003120112044637997128143121115177305364000000
-2-1-3-2-3-6-12-92-7-17-47-46-51-8-428153-1156-22-42-4915-20142156180187200224
--50.00200.00-33.3350.00100.00100.00-25.00-122.22-450.00142.86176.47-2.1310.87-84.31-50.00-800.00-46.43-80.00-133.33-1,600.00-60.00-466.6790.9116.67-130.61-233.33-810.009.8615.383.896.9512.00
0.10.10.20.20.20.30.50.50.60.70.80.91.82.705.111.111.611.611.511.8121212.616.318.1919.32000000
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The ANI Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the ANI Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (M)
RECEIVABLES (M)
OTHER REC. (M)
INVENTORIES (M)
OTHER CURRENT LIAB. (M)
CURRENT ASSETS (M)
TANGIBLE ASSETS (M)
LONG-T. INVEST. (M)
LONG-T. REC. (M)
INTANGIBLE ASSETS (M)
GOODWILL (M)
OTHER NON-CURRENT ASSETS (M)
NON-CURRENT ASSETS (M)
TOTAL ASSETS (B)
LIABILITIES
COMMON STOCK (M)
ADDITIONAL PAID-IN CAPITAL (M)
RETAINED EARNINGS (M)
OTHER EQUITY (M)
UNREAL. GAINS/LOSSES (M)
EQUITY (M)
LIABILITIES (M)
PROVISIONS (M)
OTHER SHORT-TERM LIAB. (M)
SHORT-TERM DEBTS (M)
LONG-TERM DEBT PORTION (M)
SHORT-TERM REC. (M)
LONG-T. LIAB. (M)
DEFERRED TAXES (M)
OTHER LIAB. (M)
LONG-T. LIABILITIES (M)
DEBT (M)
TOTAL CAPITAL (B)
199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
                                                     
0.15.32.64.54.99.117.39.111.530.714.829.938.257.2011.1169154.727.431.14362.37.9100.348.2221.12151.17
0000000010.500.20.1005.412.517.321.945.958.864.872.195.8128.5165.4162.08221.73
000000000000000001.201.201.103.73.900
000000000000002.83.57.513.426.237.740.548.260.881.7105.4111.2136.78
2.80.10.10.10.60.20.30.20.20.31.11.52.50.80.30.61.11.53.62.84.545.97.621.425.4218.01
2.95.42.74.65.59.317.69.322.23116.131.540.7588.527.7194.9192.7103.1131.6152.8187.7170.4321.8344.3519.82527.68
0.50.40.40.40.30.20.20.20.10.10.80.70.60.94.94.55.27.11120.438.140.641.352.743.244.5956.86
0000000000.10.13.63.43.40000000000000
000000000000000000000000000
000000000000000.110.442.166.4175.8229.8201.6180.4188.5294.1251.6209.01541.83
0000000000000001.81.81.81.81.83.63.63.627.928.228.2259.99
00000000000.60.70.10.10.2015.417.331.228.534.544.657.575.192.7102.7897.33
0.50.40.40.40.30.20.20.20.10.21.554.14.45.216.764.592.6219.8280.5277.8269.2290.9449.8415.7384.61756.01
00.0100.010.010.010.020.010.020.030.020.040.040.060.010.040.260.290.320.410.430.460.460.770.760.91.28
                                                     
13.417.717.822.326.736.756.556.76584.285.7135.3184.8255.100000000024.924.924.8524.85
000000000000001.189.5159.5164.4172.6179186.8200.8214.4387.8403.9514.1519.65
-10.8-12.2-15.6-18.3-22.1-28-40-49.7-46.9-54.5-71.9-119.4-165.6-217.2-43.8-48.5-19.7-4.4-2.9-411.517.6-5-47.8-97.3-80.13-100.28
000000-0.5-0.1000000000000-0.4-4.9-11.4-3.112.28.865.34
000000000000000000000000000
2.65.52.244.68.7166.918.129.713.815.919.237.9-42.741139.8160169.7175197.9213.5198361.8343.7467.68449.57
0.10.100.10.50.21.21.10.60.73.22.44.93.221.42.72.13.43.68.914.611.32329.336.6845.66
0.60.20.40.40.60.60.70.60.40.80.71.52.24.10.91.44.9720.42422.720.122.927.835.957.8492.67
0.1000.40.2000.93.2000000.70.85.72.68.28.318.31731.135.933.450.1146.05
000000000000004.1000000000000
000.50000000001.10000003.4115.79.913.20.90.90.859.31
0.80.30.90.91.30.81.92.64.21.53.93.98.27.37.73.613.311.73239.3165.661.678.587.699.5145.48193.68
0000000000016.717.417.348.80106.5113.4120.6198.267.3175.8172.4286.5285.7284.82615.08
000000000000000000000000000
00000000.100000000000.600.56.514.538.836.416.5346.41
00000000.100016.717.417.348.80106.5113.4121.2198.267.8182.3186.9325.3322.1301.35661.49
0.80.30.90.91.30.81.92.74.21.53.920.625.624.656.53.6119.8125.1153.2237.5233.4243.9265.4412.9421.6446.82855.17
00.01000.010.010.020.010.020.030.020.040.040.060.010.040.260.290.320.410.430.460.460.770.770.911.3
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of ANI Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand ANI Pharmaceuticals's financial health and stability.

Assets

ANI Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that ANI Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of ANI Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into ANI Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)
DEPRECIATION (M)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (M)
NON-CASH ITEM (M)
PAID INTEREST (M)
PAID TAXES (M)
NET CASH FLOW FROM OPERATING ACTIVITIES (M)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (M)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (M)
NET CHANGE IN EQUITY (M)
CASH FLOW FROM FINANCING ACTIVITIES (M)
CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (M)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
19981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-2-1-3-2-3-5-12-92-7-17-47-46-51-1028153-1156-22-42-4718
0000000000000001362227334444475959
0000000000000000-14-1-83-5-9-13-16-15-11
00000000-870-1210-80-13-9-55-14-120-5124
000000001023142167142620232731263847
0000000000000000044366692131
000000000000000001391761041001
-3-1-3-1-3-5-10-8-50-15-18-40-470-5221727396745153-31118
0000000000000000-1-2-4-10-5-6-6-2-8-8
000000-1674-1111200020-35-32-149-107-27-27-68-105-15-18
000000-1675-1111300020-34-30-144-97-21-20-62-102-6-9
00000000000000000000000000
0000000000000-11-41380075-28-30112-3-3
440349180718011486800480-10240101084
44034918071803348670-31711072-271-1194-567
00000000000220000-1400-2-100-190-12
000000000000000000000000-1-1
12-2104-7077-318819011157-14-12231119-5492-52167
-3.17-1.79-3.19-1.92-4-5.53-10.54-8.37-5.040.71-16.19-18.6-40.16-48.59-0.43-5.6720.9115.0822.929.0561.3338.999.130.76-40.08110.09
00000000000000000000000000

ANI Pharmaceuticals stock margins

The ANI Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ANI Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ANI Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the ANI Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the ANI Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the ANI Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the ANI Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the ANI Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the ANI Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the ANI Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

ANI Pharmaceuticals Margin History

ANI Pharmaceuticals Gross marginANI Pharmaceuticals Profit marginANI Pharmaceuticals EBIT marginANI Pharmaceuticals Profit margin
2030e59.27 %0 %19.83 %
2029e59.27 %15.53 %18.79 %
2028e59.27 %13.47 %18.29 %
2027e59.27 %27.94 %17.55 %
2026e59.27 %27.03 %16.68 %
2025e59.27 %26.2 %16.68 %
202459.27 %0.46 %-3.28 %
202362.71 %9.88 %3.18 %
202256.13 %-9.32 %-15.64 %
202153.45 %-12.91 %-19.81 %
202058.18 %-2.06 %-10.79 %
201969.44 %11.23 %2.91 %
201863.79 %17.56 %7.59 %
201755.32 %16.52 %-0.62 %
201662.05 %20.84 %3.03 %
201583.36 %42.86 %20.05 %
201479.46 %35.71 %51.07 %
201366.78 %2.99 %-15.61 %
201254.9 %0 %-41.18 %
2011100 %-12,725 %-12,900 %
201088 %-1,744 %-1,848 %
200976.92 %-2,953.85 %-3,653.85 %
200878.95 %-473.68 %-457.89 %
2007100 %-1,740 %-1,520 %
200675.69 %16.67 %19.44 %
2005100 %-3,366.67 %-3,233.33 %

ANI Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The ANI Pharmaceuticals earnings per share therefore indicates how much revenue ANI Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue ANI Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates ANI Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of ANI Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating ANI Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

ANI Pharmaceuticals Revenue, EBIT and net profit per share

DateANI Pharmaceuticals Sales per ShareANI Pharmaceuticals EBIT per shareANI Pharmaceuticals Earnings per Share
2030e58.55 undefined0 undefined11.61 undefined
2029e55.34 undefined0 undefined10.4 undefined
2028e53.01 undefined0 undefined9.69 undefined
2027e53.16 undefined0 undefined9.33 undefined
2026e48.51 undefined0 undefined8.09 undefined
2025e44.32 undefined0 undefined7.39 undefined
202431.8 undefined0.15 undefined-1.04 undefined
202326.76 undefined2.64 undefined0.85 undefined
202219.41 undefined-1.81 undefined-3.04 undefined
202117.15 undefined-2.21 undefined-3.4 undefined
202017.38 undefined-0.36 undefined-1.88 undefined
201917.21 undefined1.93 undefined0.5 undefined
201817.08 undefined3 undefined1.3 undefined
201715.37 undefined2.54 undefined-0.1 undefined
201611.09 undefined2.31 undefined0.34 undefined
20156.58 undefined2.82 undefined1.32 undefined
20145.05 undefined1.8 undefined2.58 undefined
20135.9 undefined0.18 undefined-0.92 undefined
20120 undefined0 undefined0 undefined
20110.15 undefined-18.85 undefined-19.11 undefined
20101.39 undefined-24.22 undefined-25.67 undefined
20091.44 undefined-42.67 undefined-52.78 undefined
20084.75 undefined-22.5 undefined-21.75 undefined
20070.71 undefined-12.43 undefined-10.86 undefined
200624 undefined4 undefined4.67 undefined
20050.6 undefined-20.2 undefined-19.4 undefined

ANI Pharmaceuticals business model

The company ANI Pharmaceuticals Inc was founded in 2001 and is located in Baudette, Minnesota, USA. ANI Pharmaceuticals is a pharmaceutical company specialized in the development and manufacturing of generic, branded, and biosimilar drugs, as well as novel therapeutic products for a wide range of diseases. ANI Pharmaceuticals has earned a good reputation over the years as a reliable provider of medications for well-known medical conditions. The company specializes in the production of prescription drugs for various conditions, including central nervous system disorders, infectious diseases, cardiovascular diseases, pain, and attention deficit/hyperactivity disorders. ANI Pharmaceuticals' business model is to provide its customers with high-quality, cost-effective, and innovative drugs. The company has an extensive portfolio of products that includes both generics and branded drugs. The company has also specialized in the production of biosimilars - bioproducts that mimic biological drugs whose patent protection has expired. ANI Pharmaceuticals pursues a differentiation strategy to strengthen its competitive position through innovative products, brand building, quality control, and cost leadership. For example, in 2019, the company developed Exservan, a liquid treatment for amyotrophic lateral sclerosis (ALS) that patients can take daily through an enlarged mouth opening. ANI Pharmaceuticals has various business segments: - Generics Business: ANI Pharmaceuticals manufactures a variety of generics for various diseases, including drugs for Parkinson's disease, pain, hypertension, and antidepressants. - Branded Product Business: ANI Pharmaceuticals also markets its own portfolio of branded products, mainly based on critical medical needs. These include Inversine - an oral medication for hypertension, Lithium Carbonate - a medication for mood disorders, and Inderal - a medication for cardiovascular diseases. - Contract Manufacturing Business: ANI Pharmaceuticals also offers contract manufacturing services for other pharmaceutical companies. ANI Pharmaceuticals provides a range of development and manufacturing services, including process development, formulation development, scale-up, validation, packaging, and distribution. - Biosimilars Business: ANI Pharmaceuticals specializes in the production of biosimilars and is working on the development of biological replicas of drugs whose patent protection has expired. This allows patients to receive a more cost-effective alternative treatment. Overall, ANI Pharmaceuticals has a strong focus on manufacturing cost-effective and high-quality medications for patients and healthcare facilities. The company has an excellent product range and is well positioned to offer innovative and highly effective drugs for the treatment of diseases in the future. ANI Pharmaceuticals is one of the most popular companies on Eulerpool.com.

ANI Pharmaceuticals SWOT Analysis

Strengths

ANI Pharmaceuticals Inc has several strengths that contribute to its success and competitive advantage. These include:

  • Strong product portfolio spanning multiple therapeutic areas
  • Established reputation and brand recognition in the pharmaceutical industry
  • Strong financial performance and steady revenue growth
  • Extensive manufacturing capabilities and vertically integrated supply chain
  • Experienced management team with deep industry knowledge

Weaknesses

Despite its strengths, ANI Pharmaceuticals Inc also faces a few weaknesses and challenges that need to be addressed:

  • Reliance on a limited number of suppliers for raw materials
  • Production and manufacturing complexities leading to potential supply chain disruptions
  • Heavy regulations within the pharmaceutical industry
  • Strong competition from larger pharmaceutical companies
  • Dependency on key distribution channels for product sales

Opportunities

ANI Pharmaceuticals Inc can capitalize on the following opportunities to drive future growth and innovation:

  • Expanding product portfolio through research and development
  • Investing in technological advancements for increased efficiency and productivity
  • Exploring new markets and geographic expansion
  • Collaborating with other pharmaceutical companies for strategic partnerships
  • Growing demand for generic and specialty pharmaceuticals

Threats

ANI Pharmaceuticals Inc should be aware of the following threats that could potentially impact its business:

  • Stringent regulatory requirements and compliance challenges
  • Increasing costs of raw materials and manufacturing processes
  • Changes in healthcare policies and reimbursement rates
  • Intense competition and price pressures in the pharmaceutical market
  • Emerging disruptive technologies and potential market disruptions
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

ANI Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

ANI Pharmaceuticals historical P/E ratio, EBIT multiple, and P/S ratio

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

ANI Pharmaceuticals shares outstanding

The number of shares was ANI Pharmaceuticals in 2024 — This indicates how many shares 19.318 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue ANI Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates ANI Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of ANI Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating ANI Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

ANI Pharmaceuticals stock splits

In ANI Pharmaceuticals's history, there have been no stock splits.
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for ANI Pharmaceuticals.

ANI Pharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20251.45 1.8  (24.28 %)2025 Q2
3/31/20251.41 1.7  (20.55 %)2025 Q1
12/31/20241.46 1.63  (11.36 %)2024 Q4
9/30/20241.11 1.34  (20.97 %)2024 Q3
6/30/20240.97 1.02  (5.26 %)2024 Q2
3/31/20241.02 1.21  (19.11 %)2024 Q1
12/31/20230.87 1  (14.67 %)2023 Q4
9/30/20230.86 1.27  (47.64 %)2023 Q3
6/30/20230.69 1.28  (85.21 %)2023 Q2
3/31/20230.36 1.17  (225.36 %)2023 Q1
1
2
3
4
5
...
9

Eulerpool ESG Scorecard© for the ANI Pharmaceuticals stock

Eulerpool World ESG Rating (EESG©)

29/ 100

🌱 Environment

9

👫 Social

36

🏛️ Governance

41

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees41
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

ANI Pharmaceuticals shareholders

%
Name
Stocks
Change
Date
12.28040 % BlackRock Institutional Trust Company, N.A.2,372,328-68,3726/30/2025
6.59219 % The Vanguard Group, Inc.1,273,47995,3166/30/2025
6.02744 % Meridian Venture Partners1,164,381-255,0003/11/2025
5.19658 % Millennium Management LLC1,003,876-112,7846/30/2025
4.46263 % Global Alpha Capital Management Ltd.862,090126,5006/30/2025
3.70699 % State Street Global Advisors (US)716,1171,5476/30/2025
3.62356 % Deep Track Capital LP700,00006/30/2025
3.27477 % Esjay L.L.C,632,620-200,0003/14/2025
2.95910 % Ranger Investment Management, L.P.571,638-6,1003/31/2025
2.94870 % Citadel Advisors LLC569,630-153,6996/30/2025
1
2
3
4
5
...
10

ANI Pharmaceuticals Executives and Management Board

Mr. Nikhil Lalwani

(45)
ANI Pharmaceuticals President, Chief Executive Officer, Director (since 2020)
Compensation 5.11 M

Mr. Stephen Carey

(52)
ANI Pharmaceuticals Chief Financial Officer, Senior Vice President
Compensation 2.04 M

Mr. James Marken

(60)
ANI Pharmaceuticals Senior Vice President - Operations
Compensation 1.43 M

Mr. Ori Gutwerg

(49)
ANI Pharmaceuticals Senior Vice President - Generics
Compensation 1.36 M

Mr. Christopher Mutz

(52)
ANI Pharmaceuticals Senior Vice President, Head of Rare Diseases
Compensation 1.3 M
1
2
3
4

ANI Pharmaceuticals Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Premier A Stock
Premier A
SupplierCustomer0,690,360,050,780,630,65
Cardinal Health Stock
Cardinal Health
SupplierCustomer0,600,37-0,20-0,74-0,54-0,20
Cipher Pharmaceuticals Stock
Cipher Pharmaceuticals
SupplierCustomer0,390,10-0,59-0,87-0,150,36
Rite Aid Stock
Rite Aid
SupplierCustomer0,39-0,110,450,830,090,01
Humana Stock
Humana
SupplierCustomer0,280,440,03-0,120,170,35
McKesson Stock
McKesson
SupplierCustomer0,19-0,40-0,56-0,90-0,200,26
Cigna Stock
Cigna
SupplierCustomer0,17-0,22-0,40-0,72-0,270,22
AmerisourceBergen Stock
AmerisourceBergen
SupplierCustomer-0,05-0,56-0,40-0,87-0,270,27
Gilead Sciences Stock
Gilead Sciences
SupplierCustomer-0,28-0,46 0,840,360,28
Walmart Stock
Walmart
SupplierCustomer-0,31-0,44-0,45-0,48-0,280,02
1
2

Most common questions regarding ANI Pharmaceuticals

What values and corporate philosophy does ANI Pharmaceuticals represent?

ANI Pharmaceuticals Inc represents values of innovation, integrity, and quality in the pharmaceutical industry. With a strong corporate philosophy centered around customer focus, ANI Pharmaceuticals consistently strives to provide effective and affordable solutions for patients. The company's commitment to excellence is reflected in their rigorous research and development process, ensuring the production of safe and reliable pharmaceutical products. With a focus on growth and expansion, ANI Pharmaceuticals continues to create value for their customers, shareholders, and employees through their dedication to continuous improvement and strategic partnerships.

In which countries and regions is ANI Pharmaceuticals primarily present?

ANI Pharmaceuticals Inc is primarily present in the United States.

What significant milestones has the company ANI Pharmaceuticals achieved?

ANI Pharmaceuticals Inc has achieved several significant milestones. In recent years, the company successfully acquired a portfolio of 23 generic drug products from Teva Pharmaceuticals, further expanding its product offerings. ANI Pharmaceuticals also obtained approval from the U.S. Food and Drug Administration (FDA) for several Abbreviated New Drug Applications (ANDAs), enabling the company to bring numerous generic products to market. Furthermore, ANI Pharmaceuticals has made substantial progress in developing a pipeline of complex generic and branded pharmaceutical products. These achievements demonstrate the company's dedication to growth, innovation, and providing high-quality medications to patients.

What is the history and background of the company ANI Pharmaceuticals?

ANI Pharmaceuticals Inc. is a leading pharmaceutical company with a rich history and strong background. Founded in 2001, ANI specializes in developing, manufacturing, and marketing prescription and over-the-counter (OTC) pharmaceuticals. The company focuses primarily on complex products, including controlled substances and niche generics. ANI Pharmaceuticals has made significant strides in the industry, expanding its product portfolio through strategic acquisitions and partnerships. With a commitment to quality and innovation, ANI has established itself as a reliable provider of high-quality medications. The company continues to grow and diversify its offerings, ensuring a positive impact on the healthcare market.

Who are the main competitors of ANI Pharmaceuticals in the market?

The main competitors of ANI Pharmaceuticals Inc in the market are companies such as Teva Pharmaceutical Industries Ltd, Mylan N.V., and Endo International plc. These companies also operate in the pharmaceutical industry and offer a variety of products and services that may overlap with ANI Pharmaceuticals. However, ANI Pharmaceuticals differentiates itself through its focus on developing and commercializing niche branded pharmaceuticals. By continuously innovating and expanding its product portfolio, ANI Pharmaceuticals strives to maintain a competitive edge in the market.

In which industries is ANI Pharmaceuticals primarily active?

ANI Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

What is the business model of ANI Pharmaceuticals?

ANI Pharmaceuticals Inc's business model revolves around the development, manufacturing, and marketing of specialty pharmaceutical products. As a specialty pharmaceutical company, ANI focuses on niche therapeutic areas such as cardiovascular, dermatology, and central nervous system disorders. By leveraging its strong research and development capabilities, ANI identifies opportunities in the market, develops new products or acquires existing ones, and then manufactures and markets them. This business model allows ANI Pharmaceuticals Inc to provide innovative and high-quality medications to patients while maintaining sustainable growth and profitability in the pharmaceutical industry.

What is the P/E ratio of ANI Pharmaceuticals 2025?

The P/E ratio cannot be calculated for ANI Pharmaceuticals at the moment.

What is the P/S ratio of ANI Pharmaceuticals 2025?

The P/S cannot be calculated for ANI Pharmaceuticals currently.

What is the Quality Investing of ANI Pharmaceuticals?

The Quality Investing for ANI Pharmaceuticals is 3/10.

What is the revenue of ANI Pharmaceuticals 2025?

The expected ANI Pharmaceuticals revenue is 856.21 M USD.

How high is the profit of ANI Pharmaceuticals 2025?

The expected ANI Pharmaceuticals profit is 142.81 M USD.

What is the business model of ANI Pharmaceuticals

ANI Pharmaceuticals Inc. is an American pharmaceutical company that is engaged in the development, manufacturing, and distribution of branded and generic drugs. The company is headquartered in Baudette, Minnesota and has a wide range of products in various sectors such as anti-infectives, cardiology, oncology, pain relief, and others. ANI Pharmaceuticals Inc. primarily focuses on the manufacturing of generics and offers a wide range of generic products, mainly distributed in the United States. They also offer contract manufacturing services for pharmaceutical products and have acquired licensing rights from other pharmaceutical companies. In addition, ANI Pharmaceuticals Inc. has a strong presence in the US market and continuously strives to expand its product portfolio and improve customer satisfaction.

What is the ANI Pharmaceuticals dividend?

ANI Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does ANI Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for ANI Pharmaceuticals or the company does not pay out a dividend.

What is the ANI Pharmaceuticals ISIN?

The ISIN of ANI Pharmaceuticals is US00182C1036.

What is the ANI Pharmaceuticals WKN?

The WKN of ANI Pharmaceuticals is A1W15D.

What is the ANI Pharmaceuticals ticker?

The ticker of ANI Pharmaceuticals is ANIP.

How much dividend does ANI Pharmaceuticals pay?

Over the past 12 months, ANI Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ANI Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of ANI Pharmaceuticals?

The current dividend yield of ANI Pharmaceuticals is .

When does ANI Pharmaceuticals pay dividends?

ANI Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ANI Pharmaceuticals?

ANI Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of ANI Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is ANI Pharmaceuticals located?

ANI Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von ANI Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ANI Pharmaceuticals from 10/2/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/2/2025.

When did ANI Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/2/2025.

What was the dividend of ANI Pharmaceuticals in the year 2024?

In the year 2024, ANI Pharmaceuticals distributed 0 USD as dividends.

In which currency does ANI Pharmaceuticals pay out the dividend?

The dividends of ANI Pharmaceuticals are distributed in USD.

All fundamentals about ANI Pharmaceuticals

Our stock analysis for ANI Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ANI Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.